Kala Pharmaceuticals KPI-012 IND Application for the Treatment of PCED Accepted by FDA

(24/7 MARKET NEWS) – Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced, after yesterday’s market close, that the FDA accepted an investigational new drug (IND) application for the company’s lead product candidate, KPI-012, a human mesenchymal stem cell secretome (MSC-S), initially in development for the treatment of persistent corneal epithelial defect (PCED).

Kala Pharmaceuticals is trading higher in this morning’s premarket, at $5.26, up $1.34 (+34.18%), on 250 thousand shares traded.

Its 52-week range is $3.5444 to $97.00. Its key inflection points are $5.00 and $5.25. It may try to challenge its early November trading levels.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist